Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Balcinrenone + dapagliflozin vs dapagliflozin in CKD with proteinuria
CTR20243343Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of balcinrenone + dapagliflozin in chronic kidney disease (CKD), sponsored by AstraZeneca. Started Sep 2024; status: completed.
02
Drugs
balcinrenone + dapagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on CTR20243343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243343.